Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Onco LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 36.00p 35.00p 37.00p - - - 0 05:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Real Estate Investment & Services 0.0 -16.5 -17.6 - 61.04

Advanced Onco Share Discussion Threads

Showing 5351 to 5375 of 5375 messages
Chat Pages: 215  214  213  212  211  210  209  208  207  206  205  204  Older
DateSubjectAuthorDiscuss
18/12/2018
08:25
Personally I still have absolutely no doubt in this company and the significant progress towards a fantastic product and high reward.
paul_98
18/12/2018
07:57
Whatever the progress and potential the market is in very unstable conditions and in the event of a market crash the worst hit stocks are likely to be those without revenue.
twirl
14/12/2018
11:05
From LSE board 3rd Dec "Harley Street, the scaffolding is coming down at the front, still plenty to do at the back but progressing well." and from 10th October RNS - Work is progressing at Daresbury Laboratory to build and prepare the test facility ready for the installation and assembly of the full LIGHT system from later this year. Some of the components of the LIGHT system have already been delivered onsite. The Science and Technology Facilities Council ("STFC") and AVO are working closely to ensure that the building work is on track to allow the installation of the LIGHT system to start next month in order to be ready for full-energy testing next year. Https://www.investegate.co.uk/advanced-oncotherapy--avo-/rns/technological-update/201810100700034752D/ Https://www.hardmanandco.com/wp-content/uploads/2018/10/AVO-Technical-update-16-October-2018.pdf To date during 2018, AVO has raised ca.£40m of cash from its new commercial partner, Yantai CIPU, and other investors, which has enabled the company to clear all its debts, provide working capital and bring additional stability. Further capital will be required, which could come from a number of sources. However, AVO, on the back of its continuous and successful operational progress, has greater flexibility now with its improved and clean balance sheet.
metis20
13/12/2018
17:07
All rather quiet here. Will be near the site on Tuesday if anyone's interested.
waterloo01
14/11/2018
17:06
Could easily be personal reasons. Not concerned.
paul_98
14/11/2018
16:44
CrazySomeone unloaded 65k shares at 39p
ishwar
31/10/2018
08:36
Nice upward turn. I suspect this will creep into the 50’s pretty soon.
paul_98
30/10/2018
11:24
(Forgot to say, thanks! for posting the link, Gregsss) A nice bit of sloppy journalism: "It reckons it can sell its technology for £20 million-£45 million rather than the current £200 million asking price............. and has sales lined up from hospital groups in the UK, Italy, France, Switzerland and China." Sales lined-up? Well that is the next big news that I think will be due. But not a fact yet.
justjill
30/10/2018
10:50
https://www.standard.co.uk/business/market-minnows-cancer-firm-advanced-oncotherapy-might-be-a-long-term-winner-a3974746.html
gregsss
12/10/2018
09:09
See recent developments and statements published on the website. Of course it’s all happening behind the scenes.
paul_98
12/10/2018
08:37
But when? It takes a long time for any company to become established and ramp up everything. AVO is likely to be bleeding cash and not be profitable for years. It could be the mid 2020s before AVO breaks even, if then. It is the nature of new companies.
daijavu
11/10/2018
17:40
Absolutely convinced that orders will come and plenty of them.
paul_98
11/10/2018
10:18
Yes some sign of revenue is important esp in uncertain markets where anything with no revenue and potentially requiring further funding is less favoured.
twirl
11/10/2018
10:07
The thing is Daijavu, the long-term board are mostly scientists/clinicians...though experts in their field. I think that that is why they messed up before in a pure business-sense and got into the so-called death spiral. But the make-up of the company is now very different, incl eg major shareholders. I think huge progress has been made in the science/Tech,....and that is what was needed. Everything else gets built on that. As I said on the other thread, what they need to do now is get some orders in. I think that really could be transformational in terms of the business/shareholders.
justjill
11/10/2018
10:01
Maybe you're right Twirl. But I think at least any placing would be underpinning huge progress in the science/Tech,....and that is what was needed. Everything else gets built on that. What they need to do now is get some orders in. I think that really could be transformational in terms of the business/shareholders.
justjill
11/10/2018
09:36
It would be nice if AVO came good but I still have reservations about the BoD.
daijavu
11/10/2018
07:26
This flurry of releases esp the paid for goetz "research" tip designed to prop up the sp, smells of a placing in the offing.
twirl
10/10/2018
16:49
That was certainly the start of a much needed upturn.
paul_98
10/10/2018
06:46
Flash note now published on AVO website also! hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xzze87x
makeamillion1
10/10/2018
06:17
hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xompdmr
makeamillion1
10/10/2018
06:09
hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xompdmr The company is making very good progress! Excellent Technological Update today!
makeamillion1
05/10/2018
11:59
Still on track....STFC's Daresbury Laboratory gears up to test next generation of cancer treatment?Computer aided design image of the new facility.(Credit: STFC)In May, STFC's Daresbury Laboratory signed a major agreement with British company Advanced Oncotherapy, to build a mass assembly and testing centre for the world's next generation of proton therapy to treat cancer.The technology behind Advanced Oncotherapy's LIGHT system, span out of CERN, the home of the Large Hadron Collider, and is designed to reduce the cost and improve the performance of proton therapy to treat cancer and will be a significant milestone advancement in cancer therapy.Work is now progressing at Daresbury Laboratory to build and prepare the test facility ready for the installation and assembly of the full LIGHT system from later this year.STFC's Neil Bliss, who is managing the project said: "Things have been extremely busy, we're completing project milestones to a strict schedule to ensure that everything is coming together, on track for Advanced Oncotherapy's LIGHT system installation next month, ready for full-energy testing next year. The concrete shielding for the proton injector and RF test bunkers are in place. At the same time, the supporting steel work and the necessary electrical installations are well underway. This is just a snapshot of the design and planning activities taking place behind the scenes in preparation. We're thrilled that Daresbury Laboratory's expertise in particle accelerators and facility construction are contributing towards what will be a key milestone advancement in proton therapy."Read more: STFC's Daresbury Lab to test next generation of cancer treatment.Proton therapyProton therapy produces fewer side effects than conventional radiotherapy. It uses beams of protons to precisely target cancerous tumours while limiting damage to surrounding organs or tissue. Offering higher disease-free survival rates, proton therapy is most often used to treat brain tumours in young children whose organs and tissues are still developing, or cancers adjacent to critical part of the body (liver, lung, head and neck, prostate, breast).
rpctech66
30/9/2018
16:33
The technological advances far outweigh things here now. I expect gains.
paul_98
30/9/2018
14:19
Have got round to reading the results and am shocked to see that they only had £3.3m of cash at the interim stage despite having raised so much. They obviously raised £6.4m after that date but once again they look very low on cash and it looks as if they'll need to raise cash again. I'd also note that the "license fee" hasn't been recognised in the revenue line and is showing in the balance sheet as a liability. That suggests that it's refundable in some sort of circumstance - like the last time that they did a deal with the Chinese company. I suspect that the shorters will be coming back to AVO.
jaknife
28/9/2018
17:06
I'm not. It is quite usual for the market not to notice, especially in the case of small companies like AVO who have no income and, as far as most people are concerned, no clear prospects. It takes people like us who have an exceptional interest in the company to notice. I've dipped my toe in again and I hope I don't regret it.
daijavu
Chat Pages: 215  214  213  212  211  210  209  208  207  206  205  204  Older
Your Recent History
LSE
AVO
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181219 07:34:40